ERBB2 and breast cancer: Molecular classification revealed that 40 patients (40.4%) had luminal B BC, 18 (18.2%) had luminal A BC, 13 (13.1%) had HER2-enriched BC, while 18 (18.2%) had triple-negative BC and 10 patients were undetermined.